ABSTRACT
(dichloride (2,2'-bipyridyl) aurate(III)-ion), on the murine BCL-1 B lineage leukaemia cell line. The cytotoxicity of these gold(III) complexes was evaluated by cytotoxic assay (MTT test). The results showed that all of the tested gold(III) complexes displayed a cytotoxic effect on BCL-1 cells. The concentration decrease was followed by a marked increase in BCL-

INTRODUCTION
The success of cisplatin, carboplatin and oxaliplatin, which now play a major role in established medical treatments of cancer, has aroused great interest in the study of the cytotoxic effects of metal complexes that are isostructural to these platinum complexes [1] [2] [3] .
During the last twenty years, much research has focused on gold(III) complexes, which are square-planar d8, isoelectronic and isostructural to platinum(II) complexes. Many in vitro and in vivo studies have been conducted to investigate and precisely describe the mechanism underlying the anti-tumour effects of gold(III) complexes [3] [4] [5] [6] [7] . Although the results were encouraging and gold(III) compounds appeared to be very good candidates for anticancer drugs [4] [5] [6] [7] , because of their reductive potential, these complexes were not stable under physiological conditions [8] . Therefore, the selection of a suitable ligand to stabilise the complex became a foremost challenge in the de-sign of new gold(III) complexes with one or more multidentate ligands that enhance the stability of the complex.
We BCL-1 is a murine B lineage leukaemia cell line that was first described by Slovin and Straber [9] . BCL-1 leukaemia arose spontaneously in a 2-year-old BALB/c mouse and is easily transplanted in syngeneic recipients by injection of spleen or peripheral blood lymphocytes previously obtained from leukaemic animals [10] . BCL-1 leukaemia represents an experimental model for human chronic prolymphocytic leukaemia (PLL) [11] . The analysis of BCL-1 cell morphology showed that these cells closely resemble the prolymphocytes obtained from patients with prolymphocytic leukaemia [10] [11] . Further, BALB/c mice injected with BCL-1 cells develop enlarged spleens diffusely infiltrated by BCL1-prolymphocytes [10] [11] . In accordance with massive splenomegaly, the murine BLC-1 leukaemia is characterised by leukocytosis (white blood cell counts >10 8 /ml), hepatomegaly and little or no lymphadenopathy [11] .
This study could shed elucidate the in vitro anti-cancer properties of selected gold(III) complexes and indicate the value of investigating some of these newly synthesised gold(III) complexes in future studies.
MATERIALS AND METHODS
Chemicals and ligands
The ligands 2,2'-bipyridyl (bipy) and (1R,2R)-1,2-diaminocyclohexane (dach) were obtained from Acros Organics, while the ligand ethylenediamine (en) was obtained from Sigma-Aldrich (Munich, Germany). The starting potassium tetrachloridoaurate(III) complex, K[AuCl 4 ], was purchased from ABCR GmbH & Co (Karlsruhe, Germany), while cisplatin (cisdiamminedichloroplatinum(II), cis-[Pt(NH 3 ) 2 Cl 2 ]) was purchased from Sigma-Aldrich. All chemicals were of the highest purity commercially available and were used without further purification.
For the cytotoxicity determination, further chemicals were used, including foetal bovine serum (FBS), growth medium RPMI 1640, penicillin G, streptomycin, (3-(4,5)-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium-bromide (MTT), phosphate buffered saline (PBS), dimethylsulfoxide (DMSO), trypan blue stain (all from Sigma Chemicals, Germany) and Haemaccel (Theraselect Gmbh, Germany). The assays were performed in 96-well plates (Sarstedt, Germany). 
Synthesis of the complexes
Cell culture
The BCL-1, murine B lineage leukaemia cell line, syngeneic in BALB/c mice, was purchased from the American Type Culture Collection (ATCC) Manassas, VA, USA. The BCL-1 cells were cultured in RPMI 1640 medium with 2 mM L-glutamine and 0.05 mM 2-mercaptoethanol containing 15% FBS, 100 IU/mL penicillin G and 100 μg/mL streptomycin (Sigma-Aldrich chemical, Munich, Germany). BCL-1 cells from the third passage were used throughout these experiments. + complexes on BCL-1 cell viability were determined using the MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) colorimetric test [15] .
Cytotoxicity assay
BCL-1 cells were diluted with medium to 1 x 10 5 cells/ mL, aliquots (1 x 10 4 cells/100 μL) were placed in individual wells in 96-well plates, and 100 μL of complexes diluted in medium in selected concentrations were added. Cells were treated with selected concentrations of complexes for three days. Control wells were prepared by adding culture medium. Wells containing culture medium without cells were used as blanks. The MTT solution was prepared as 5 mg/ml in PBS just before use and filtered through a 0.22-μm filter. After incubation, the cells were pelleted, and the drug-containing medium was discarded and replaced with serum-free medium containing 15% MTT solution. After an additional 4 h of incubation at 37 °C in a 5% CO 2 incubator, the medium with MTT was removed, and DMSO (150 μL) with glycine buffer (20 μL) was added to dissolve the blue formazan crystals. The plates were shaken for 10 min. The optical density of each well was determined at 595 nm.
The percentage of cytotoxicity was calculated using the following formula:
% of viable cells = (E−B)/(K−B) × 100 where B is for the background optical density of the medium alone, K is for the total viability/spontaneous death of untreated target cells, and E is for the experimental well.
STATISTICAL ANALYSES
Where appropriate, the data were presented as means +/-SD. Statistical analyses were performed by ANOVA followed by the Bonferroni test. The level of significance was set at p < 0.05.
RESULTS
All three of the gold(III) complexes showed cytotoxic effects on BCL-1 cells (Figures 1 and 2) .
At concentrations from 3.9 μM to 125 μM, all of the tested complexes showed similar and low cytotoxic effects. + was still high (approximately 67%).
It is interesting to note that the cisplatin complex showed high and dose-independent cytotoxicity on BCL-1 cells (Figures 2 and 3) . + gold(III) complexes on the BCL-1 murine B lineage leukaemia cell line. Our results showed that all of the tested gold(III) complexes displayed cytotoxic effects on BCL-1 cells (Figures 2 and 3 ). The concentration decrease was followed by a marked increase in BCL-1 cell viability (Figure 3) .
At the concentration of 125 μM, which we suppose could be used in vivo, the [Au(bipy)Cl 2 ]
+ complex showed the greatest cytotoxic effects among the tested gold(III) complexes and similar cytotoxicity compared to the cisplatinum control. At 125 μM, only 24 hours after treatment with [Au(bipy)Cl 2 ] + , almost all of the BCL-1 cells were dead (Figure 3) .
Recently, described activation parameters for kinetic reactions important for the synthesis of the tested complexes [16] [14, [16] [17] , the first reaction step occurs via nucleophilic attack of the N7 donor atom of the purine base in 5'-GMP, resulting in the formation of a product by the departure of one chloride ion. The second step includes the substitution of another chloride ion from the starting complex, when 1:2 complexes are formed. + complex. Although the cisplatin complex shows high cytotoxicity on BCL-1 cells, it was previously reported [4] that gold(III) complexes are better tolerated in vivo because of the different anticancer mechanisms utilised by gold complexes and cisplatin. The main anticancer mechanism of the cisplatin complex is its interaction with DNA. The cisplatin complex forms an adduct that interferes with transcription and replication, which is followed by apoptosis of the cancer cell [18] . The interactions of cisplatin with DNA result in a Pt-GG intrastrand crosslink that is the critical lesion leading to cisplatin toxicity dominantly manifested by dysfunction of gastrointestinal and haematological systems [18] [19] . Although the main intracellular target for gold(III) complexes and the precise mechanisms responsible for their anticancer effect are still unknown, some recently published data suggest that their mechanisms of action, such as modification of surface protein residues and inhibition of proteasome function [20] , are substantially different from that of the cisplatin complexes.
In view of our results, we suggest that the [Au(bipy)Cl 2 ] + complex should be tested in vivo in experimental models of B cell leukaemia.
